ERBB2 and breast carcinoma: An advantageous impact of HER4 expression in breast cancer has been mechanistically attributed to a ligand (i.e., heregulin) dependent receptor activation and subsequent trigger of differentiation pathways that in turn antagonize oncogenic cellular features generated not only but also by other coexpressed HER receptor family members, above all HER2 [12, 13].